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S _q The aim of this study was to assess the practicality of treating patients with various stages of
breast cancer by means of regional (intra-arterial) . Tlhree groups of patiets received a median
of four (range 2-4) cyces of combination group I operab primary (n = 10); group II, localy
advanced diseas (n
= 20); group HI, remrrent kocrgioal disea (n
= 22). The response rates (complte
response, partial response and mixed response) in these groups of patients we 100%/ in groups I and II and
86% in group Im. Morbidity induded drug steaming and dysaesthesia m the hand. Patients m groups I and H
had their tumours downstaged, allowing surgey to be performed. Local control was also achieved in group HI
when other treatment modaities had failed.
Kewismr breast cancer, chemotherapy; intra-arterial chemotherapy
Advanced and recurrent breast cancer treated with chemo-
therapy will result in response rates in the region of 15-80%,
depending on the stage of disease and the type of pretreat-
ment. Many breast cancers have been shown to be chemosen-
sitive in vitro, but one of the factors limiting clnical efficacy
is the dfculty in achieving adequate drug concentrations
because of systemic toxicity. The local concentration of a
drug may be incsed by administraton via the arterial
route. Intra-arterial chemotherapy has been ini
previously in the treatment of breast cancer (Hehnan, 1968)
but was not widely adopted because of the lack of suitable
catheters, concern over the possibility of arterial thrombosis
and ignorance concerning the phamacokinetics of the drugs
used.
The aim of this study was to determine the feasibility of
treating patients with various stages of breast cancer by
means of intra-arterial chemotherapy. Two questions have
been addressed. Firstly, what is the efficacy of this treatment
in obtaining local control of the breast cancer? Secondly,
what price in terms of toxicity and morbidity might such
treatment extract from the patients? It was our hypothesis
that intra-arterial chemotherapy would allow higher dosages
of drug to be given to the region of the breast, thus enhanc-
ing the beneficial effect without the downside potential of
mcreasing systemic toxicty.
Patlets and method
Fifty-two patients with breast cancer were studi. The
details of the patients are given in Table I. Group I patients
(n = 10) were patients with 'early' disease (12, NO-NI, MO)
who ekcted to undergo this treatment after full counslling
regarding other 'conventional' forms of therapy. This group
ofpatients underwent a kvel II axillary dissection at the time
of plaement of the intra-arterial catheter. The first dose of
mitoxantrone was given as a 30min infusion on day 2, and
further infusions were given on days 24, 52 and 76. The
tumour was resected on day 52. Group H patients (n
= 20)
were patients with locally advanced disease (T3-T4, NO-N2,
MO-MI). Group III patients (n = 22) were patients with
recurrent locoregional disease.
An infraclaviular approach to the subclavian artery was
used in the majority of cases. Alternative approaches include
a supraclavicular approach on the right side and an axillary
approach on either side. A 5-0 non-absorbable pursesting
suture was inserted into the anterior surface ofthe artery and
a catheter was introduced through a stab incision. The
used were the Jet-Port Plus Long (PFM, Cologne,
Germany) or a Pulmoplant (B.Braun. Mesungen, Germany).
Both catheters are fine-bore plastic with an attachable port
for subcutaneous implantation. The mouth of the catheter
was placed at the opening of the internal mammary artery,
the port temporarily connected and the position confirmed
by an injection of non-ionic contrast medium under radiog-
raphic control. An injection of 2-4 ml of filtered methylene
blue was then given, which usually produced a clear stain in
the tumour or reurren together with a faint blue outine
over the chest wall. The catheter was shortened and a sub-
cutaneous pocket for the injection port was created on the
chest wall. The patient received the first drug infusion the
following day usng a Surecan needle (Braun) to acss the
subcutaneous port.
More recently a transfemoral arterial approach has been
used to access the catheter with the aid of our collagues in
the Department of Radiology, and the drug infusion given
on the same day (Figure 1). If the aim is to treat the whole
chest wall then the catheter is plaed within the subclavian
artery, but if a more locaised approach to the breast is
required then the catheter can be specifically plced in the
origin of the internal thoracic or lateral thoracic arteries.
The drug regimens used are shown in Table H. Each drug
was delivered in 25 or 50 ml of 0.9% saline and infused at a
rate of 100 ml h-' using a Graseby (Watford, UK) syringe
driver. A sphygmomanometer cuff, inflated to 10 mmHg
Tabek I Details of the patient
Group I II III
No. of patients 10 20 22
Median age (years) 52 (42-63) 57 (37-78) 50 (38-75)
(rage)
Stage of disease
TXN2MO 1
T2NO 9
T2NI 1
T3NOMO I
T3NlMO 9
T3N2MO 2
T3N2M1 I
T4NOMO I
T4NIMO 3
T4NIM1 2
Median follow-up 42 (35-45) 13 (1-52) 14 (1-31)
(months) (range)
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above systolic blood pressure, was used during the infusion
of mitoxantrone and the vesicant drugs mitomycin C and
adriamycin to prevent flow into the arm. All patients were
prescribed dipynrdamole 100 mg t.d.s. for 1 month after
operative line placement as prophylaxis against arterial
thrombosis. Chemotherapy was withheld if the patient
suffered a neutropenia with a white cell count of less than
3.0 x 10 1V' or platelet count less than 100, and if this was
persistent the dose of chemotherapeutic agent used was
reduced by 50%.
>^KI
Fire 1 Arteriogram demonstrating catheter placement at
opening of internal mammary artery.
Table II Details of the chemotherapeutic regimens
MALF
Mitomycin C 14mg given in 25 ml on day 1'
Adriamycin 30 mg given in 25 ml on day 2a
Leucovonrn 50 mg given together mixed in 50 ml
5-Fluorouracil 1000mg J on days 1. 2 and 3.
ALF
As MALF without the mitomycin C
MMM
Mitomycin C' 14 mg in 25 ml
Mitoxantrone 20mg in 50 ml
Methotrexate 50 mg in 25 ml
M
Mitoxantrone given as a single agent in 50 ml at the doses indicated
above.
'Given with an arm tourniquet. These regimens were given four
times at intervals of 4 weeks usually on an outpatient basis. Group I
patients received treatment at slightly different time intervals as
stated in text. All patients received dypiridamole 100 mg t.d.s. for the
first cycle.
Patients in groups II and III were assessed clinically and
when relevant photographed after each course of treatment.
After removal of the intra-arterial line the patients were
followed until death.
Clinical response
Clinical responses were defined according to UICC cnrtena.
A complete response (CR) was defined as the disappearance
of all local disease as assessed clinically, i.e. healing of ulcers,
disappearance of nodes, restoration of normal breast con-
tour. A partial response (PR) was defined as a decrease by at
least 50% in the sum of the products of the largest perpen-
dicular diameters of all measurable lesions plus the sum of
the diameters of all evaluable lesions as determined by obser-
vations not less than 4 weeks apart.
Toxicity
Toxicity was assessed and graded according to the World
Health Organization grades by the breast care sister (VAW).
With reference to symptoms from the hand and arm, these
were classified from 0 to IV (0 = none, I = paraesthesia and
or decreased tendon reflexes, 11= severe paraesthesia and/or
mild weakness, III = intolerable paraesthesia and/or marked
motor loss, IV = paralysis.
Histological response
In group I the response of the breast tumour was evaluated
using histological method described by Shimosato et al.
(1971) and modified by Noguchi et al. (1988):
Grade I: cancer cells were degenerated, but cellular
arrangement was preserved.
Grade Ila: viable cancer cells remained in more than 25%
of the area of the lesion.
Grade Ilb: Viable cells remained in 25% or less.
Grade III: no cancer cells were present.
Grade IV: cancer cells were replaced by fibrosis.
An average of 15 blocks were examined (range 9-41) to
ensure an accurate assessment of response.
Results
Response
All patients showed some response in that a reduction in the
size of the tumour was seen or the number of recurrent
nodules reduced. Many patients achieved a complete clinical
response. The number of recurrences and the time to recur-
rence are shown in Tables III-IV.
Morbidity
The side-effects observed may be classified as systemic (those
to be expected after chemotherapy) and regional (arm) side-
Table m Details of outcome in group I patients (primary operable
disease)
Patient TNM stage Regimen Response Outcome
JD T2NOMO M20 mg I Lump a+w 45112
EM T2NOMO M20 mg Ila Lump a+w 44/12
NJ T2NOMO M20 mg Ilb Lump died 38/12
JW T2NOMO M25 mg Ila Lump a+w 44A12
SM T2NOMO M25 mg I Lump, loc rec 2712,a
Mast a+w 42/12
MS T2NOMO M28 mg III Lump a+w 42/12
PR T2NOMO M28 mg I Lump a+w 37 12
MB T2NOMO M31 mg I Mast a+w 37,12
KH T2NlMO M31 mg IIb Mast a+w 37,12
MC T2NOMO M31 mg III Mast a+w 35/12
aLocal recurrence in area infused. Response assessed histologically
(see text). Lump. lumpectomy; Mast, mastectomy.Regona dm_m apy for hreus cancer
WG Lewis etal
Tabk IV Details of outcome in group II patients (locally advanced
disease)
Patient TNM stage
BB T3NIMO
MS T4NIMO
JN T4NIMO
DW T4NIMO
PB T3NIMO
CE TXN2MO
CC T3NIMO
JP T3NOMO
YF T3N1MO
MB T3N1MO
MS T3N2MO
Mi T3NIMO
MW T3N2MI
Regimen Response
MALF CR
MALF PR
MALF CR
MALF PR
MMM CR
MMM CR
M 31 mg PR
M 31 mg
MMM
MMM
MALF
MMM
CR
PR
CR
CR
PR
MMLF PR
JH T3N2MO MALF PR
MK T3NIMO MMLF CR
MT T4NIMX MALFx INA
MH T4NOMO MALFx INA
MW T3NIMO MALF CR
CB T3NIMO MMx2 PR
JR T4NIMO MMx2 PR
Outcome
Lump a+w 52,12
died 3A12 20
died 10 12 2'
Mast died 13/12 2'
Mast died 13/12 2-
Loc rec 10/12
died 16/12 2'
Mast loc rec 26 12
died 30/12 2'
Mast a+w 30 12
Mast died 19/12 2'
Mast died 17/12 2'
Died 3/12 2-
Mast loc rec 15/12
died 22/12 2'
Loc rec 3 12
died 8/12 2-
Mast died 1/12 NCRD
mast a+w 20/12
Died 6/12 2'
Died 1/12
Mast loc rec 8/12
Mast a+w 9/12
Died 7/12 2-
Response assessed clinically: CR, complete response; PR, partial
response (see text). Mast, mastectomy; lump, lumpectomy loc rec,
local recurrence, 2-, distant metastases; x I or x2, one or two cycles
of treatment only given.
Table V Details of outcome in group III patients (recurrent
locoregional disease
Patient Regimen Response Outcome
EB M28 mg CR Loc rec 5.12 died 31/12 2'
LS M31 mg CR Loc rec 10/12 DXT died 19/12 2'
MB MALFx2 PR Died 6/12 2'
DB MALFx2 CR Died 18/12 NCRD
MT MALF CR Died 14/12 2@
BB MALF CR Loc rec 6/12 died 17'12 2'
NL ALFx3 MR Died 3/12 NCRD
DC MALFx3 CR Loc rec 4/12 DXT a+w 25'12
MC MALFx2 CR Died 6112 2'
CLG MALF PR Died 1'12 2'
BB MALF PR Died 1/12 NCRD
BJ MMM MR 2' 11/12 alive at 20,12
SY MALFx3 PR Loc rec 3 12 alive at 19 12
DW MMx 1 NA Artenral thrombosis
SW MMx2 NA 2'
EL MMx2 PR Died 2/12 2'
JP M PR Surgical clearance a+w 11 12
IC MM CR a+w6/12
CS MM CR Mast a+w 712
JT MM PR Surgical clearance a+w 6,12
CA ALF PR a+w 612
ET MMx5 CR a+w at 2,12
Response assessed clinically; CR, complete response; PR, partial
response; MR, mixed response. NA, not applicable; NCRD,
non-cancer-related death.
o I
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No tourniquet Tourniquet
Figre 2 Arm symptoms after intra-arterial chemotherapy by
WHO grade. Figures are median (interquartile range). The effect
of a brachial tourniquet on the incidence and grade of arm
symptoms is clearly apparent.
Figure 3 Skin pigmentation after one
chemotherapy.
course of intra-arterial
effects. This morbidity is summarised in Table IV. Before a
sphygmomanometer cuff was introduced some patients
experienced paraesthesia affecting the fingers which was
occasionally associated with causalgia. This has subsequently
resolved in most patients. Such problems have been
encountered significantly less often with the use of a brachial
tourniquet. Fifty five per cent of patients suffered significant
symptoms before the introduction of a tourniquet compared
with only 9% of patients in whom a tourniquet was used
(P = 0.0067) (Figure 2). Of the ten patients with arm symp-
toms of grade 2 or greater, five improved to grade 1, the
median time for this improvement being 31 months (range
3-54 months). Of the remaining five patients, three have died
and two still have significant arm symptoms at 30 and 48
months post chemotherapy. Many patients developed
pigmentation of the area treated, which resolved after com-
pletion of treatment (Figure 3). Drug streaming occasionally
resulted in a chemical dermatitis affecting a small area of
skin with erythema and pruritus, which is likely to be due to
linear flow in the main artery resulting in very high levels of
drug passing into small cutaneous vessels. This responded to
topical Caladryl lotion (Warner-Lambert Health Care, East-
leigh. Hampshire, UK). Eleven patients in all (three in group
2 and eight in group 3) had to have their treatment delayed
because of haematological side-effects (11 patients with neut-
ropenia, three with concomitant thrombocytopenia), however
all patients recovered and completed the course of
chemotherapy.
D6uson
The blood supply of the breast is derived from the internal
thoracic (mammary) artery and the lateral thoracic arteries.-w WG Lewis et a
TaTl VI Number of patients with toxicty by WHO grade
WHO grade 0 1 H IH IV
Group I
Nausea/vomiting 1 5 3 1 0
Alopecia 0 9 1 0 0
Haematological 3 5 1 1 0
Arm 3 5 1 1 0
Group II
Nausea/vomiting 5 7 8 0 0
Alopecia I 11 5 3 0
Haematological 14 3 0 3 0
Arm 13 4 0 3 0
Group III
Nausea/vomiting 6 6 8 2 0
Alopeia I 111 5 5 0
Haematological 13 2 4 3 0
Arm 13 2 4 3 0
Tabe VII Summary of response of patits tomita-arteri
chemotherapy
Group
I II Hi
Number of patients 10 20 22
Response
Complete 10 9 (45%) 10 (41%)
Partial 9 (45%) 8 (36%)
N/A 2 2
Duration of response N/A 10 (3-26) 5 (3-10)- (months)
Surgicalcearance 10 12 3
Alive and wel 9 (90(/.) 4 (201'/.) 3 (14%)
NA, not applcabe.'Median (range) time to relapse.
The possible advantages of using this route to deliver
chemotherapy directly to the field of the tumour are clear.
Firstly, a higher local concentration of drug in the tumour
field may be achieved than would be the case using the
systemicintravenous route. Typially, dosages of drugs
admnistered intra-arterially may be up to 25% higher than
those administered intravenously (Aigner et al., 1988a),
which would certainly result insignificnt systemic toxcity.
Secondly, spillover of the chemotherapeutic agents into the
circulation may produce a general adjuvant effect.
Additions to the bank of active chemotherapeutic agents
have been few in recent years. An alternative approach to
improving results is to increase the doses of drugs currently
in use. Onelimiting factor in terms of toxcity is the effect of
these agents on the patients' bone marrow. The aministra-
tion of granulocyte colony-stimulating factors has been
shown to reduce bone marrow toxicity (Deveroux and Linch,
1989), while transplantation of autologous bone marrow
allows higher dosages of chemotherapy to be given (Jones et
al., 1990). Both of these techniques have resulted in higher
rates of response but are not yetin common use because of
the assocated expense and toxicty. In addition, such app-
roaches have not yet been shown to improve disease-free or
overall survival rates (as is also the case for intra-arteria
chemotherapy).
The theoretical advantages of intra-arterial chemotherapy
cited above would appear to be borne out in practie, and
certainy the results of this study support our initial
hypothesis. The responses rates observed in groups I and II
were excellent with no fewer than 22 patients going on to
receive surgery to their downstaged cancers. Moreover, the
response was rapid, usually within two cycles of treatment.
Patients in group IIH also experienced a good response,
though this was less so than in groups I and II - a rltion
of the heavy pretreatment which this group had usually
undergone. These results therefore agree with those of other
workers in this fiekl, who have reported response rates of
between 83% and 92% (Aigner et al., 1988b; de Dycker et
al., 1988; Nogucchi etal., 1988). An alternative for patients
in group II I might be continuous-infusion therapy, because
even using the intra-arterial approach the drug concentra-
tions achieved within the tumour may not be sufficient, and
an infusional approach mayallow higher steady-state con-
centrations. Aigner etal. (1988b) were the first to report the
decreased rate of response in patients who had already
received radiotherapy and chemotherapy. Radiotherapy
results in an endarteritis, preventing the drug from reaching
its target; chemotherapy reduces the patients' bone marrow
reserve, lmiting the dosages of drugs that may be used. It
has been shown that patients who have had no pretreatment
fare much better (Stephens, 1988; Aigner etal., 1988b), which
suggests that intra-arterial chemotherapy may have a role as
a first-ie therapy, perhaps followed by radiotherapy and
possibly surgery. It is also of note that higher grade tumours
(Bloom and Richardson grade H and II) demonstrated a
more marked response than lesser grades of tumour (Sains-
bury etal., 1991).
The disadvantages of this form of therapy have proven to
be local toxicity, i.e. problems with thefunction of the arm
on the ipsilateral side. This is in contrast to the reports of
other clnicians (Aigner etal., 1988b; de Dycker etal., 1988;
Nogucchi etal., 1988; Stephens, 1990), of whom only Noguc-
chi etal., reported any local morbidity in the form of slow
wound eaing with certainregimens. Local toxicity was
usually clinically manifest as paraesthesia affecting the
fingers, occasionally with associated causalgia and loss of fine
motor fumction. Intestingly, such local toxicity did not
appear to be related to the regimen used, nor was it more
pronouncedin the patients withrecurrent locoregional
disea.Electromyography demonstrated a degeneration in
the axons of both sensory and motor nerves. However, all
patients have improved with further follow-up, and there has
been a significant reduction in such toxicity sinc the use of
brachial tourniquet during infusion of the dmg was com-
mnced. This problem has been further diminished since the
use of radiological placement of thelines.
The role ofchemotherapy in the treatment of patientswith
breast cancer is an evolving one. Patients with locally
advanced primary disease, inflammatory disease and patients
who refuse mastectomy arebeing treated with intravenous
induction chemotherapy by the Royal Marsden Hospital
(Mansi et al., 1989) and other groups (Zylberberg et al.,
1982; Loprinzi et al., 1984). Intra-arterial chemotherapy has
been used for advanced breast cancer in a few studies by
means of vanous approaches and drugregns (Freckman,
1970; Aigner et al., 1988b; de Dycker et al., 1988; Stephens,
1990), and has also been used with some suss in an
attempt to control haemorrhage from fungating breast
lesions (Rankin et al., 1988).The technique is still very much
in its infancy, and thus there are areas whereimprovements
in technique may be made with a view to reducing the
associated morbidity, in particular the local neurotoxicity
affecting the arm. Itrenains to be seen whether the advan-
tages oflong-term disease control will outweigh the potential
disadvantages of this technique. Nevertheless, intra-arterial
chemotherapy does offer a new way of inducing tumour
regression prior to surgery, and for patients with end-stage
recurrent chest wall disease, who would otherwise have little
further hope, this approach mayrepresent the only treatment
available whereby a response may be achieved. Further tech-
nical advances such as blocking of the distal interal mam-
mary artery to reduce run-off and super-selctive placement
of lines may yet increase the therapeutic benefit. Combina-
tions of this regime with hyperthrmia are under study as are
the use of position e uission tomography (PETf)nning to
try and determine the vascularity and perfusion of tuiour
tissue. This technique may provide guidance as to which
patients are unsuitable for intra-arterial therapy.
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